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Abstract
Background: Hormone replacement therapy (HRT) is widely used and has proven benefits for women with
menopausal symptoms. An increasing number of women with cancer experience menopausal symptoms but the
safety of HRT use in women with cancer is unclear. There are particular concerns that HRT could accelerate cancer
progression in women with cancer, and also that HRT could increase the risk of cardiovascular disease in such
women. Therefore, our primary aim is to determine whether HRT use alters the risk of cancer-specific mortality in
women with a range of common cancers. Our secondary objectives are to investigate whether HRT alters the risk
of second cancers, cardiovascular disease, venous thromboembolism and all-cause mortality.
Methods: The study will utilise independent population-based data from Wales using the SAIL databank and
Scotland based upon the national Prescribing Information System. The study will include women newly diagnosed
with common cancers from 2000 to 2016, identified from cancer registries. Women with breast cancers will be
excluded. HRT will be ascertained using electronic prescribing in Wales or dispensing records in Scotland. The
primary outcome will be time to cancer-specific mortality from national mortality records. Time-dependent cox
regression models will be used to calculate hazard ratios (HR) and 95% confidence intervals (95% CIs) for cancer
specific death in HRT users compared with non-users after cancer diagnosis after adjusting for relevant
confounders, stratified by cancer site. Analysis will be repeated investigating the impact of HRT use immediately
before cancer diagnosis. Secondary analyses will be conducted on the risk of second cancers, cardiovascular
disease, venous thromboembolism and all-cause mortality. Analyses will be conducted within each cohort and
pooled across cohorts.
Discussion: Our study will provide evidence to inform guidance given to women diagnosed with cancer on the
safety of HRT use and/or guide modifications to clinical practice.
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Background
Menopausal hormone replacement therapy (HRT) is
widely used globally [1] and has been shown to reduce
menopausal related vasomotor symptoms (hot flashes,
flushing, and night sweats) and urogenital atrophy [2].
HRT preserves bone mass and is approved by the Food
and Drug Administration to prevent postmenopausal
osteoporosis [3]. It has also been shown to reduce joint
pain, mood swings, sleep disturbances and improve qual-
ity of life [2]. Consequently, it has been acknowledged
that a reluctance to treat menopausal symptoms can
cause unnecessary suffering [4, 5].
Use of HRT in women with cancer
An increasing number of women with cancer experience
menopausal symptoms. HRT is contraindicated in pa-
tients with breast cancer and oestrogen-dependent can-
cers [3, 6, 7] but not in patients with other cancers and
authors have argued against the denial of HRT in these
patients except when based upon evidence, given the
benefits of HRT [8]. Numerous researchers have made
recommendations, based upon limited evidence, for and
against the use of HRT in patients with cancer depend-
ing upon the site of their cancer [8–10].
HRT and cancer-specific mortality
Various studies have provided evidence suggesting that
oestrogen may accelerate the progression of certain can-
cers. For instance, preclinical studies suggest that
oestrogen stimulates growth in bladder [11] and gastric
cancer cell lines [12] and lung cancer mouse models
[13]. Also, observational studies have shown increases in
the risk of glioma and meningioma with use of
oestrogen only HRT [14] and the Women’s Health Ini-
tiative trial showed a marked increase in death from
lung cancer in the oestrogen plus progestin group com-
pared with placebo (HR 1.71, 95%CI 1.16 2.52) [15].
Despite this suggestive evidence, there have not yet been
any epidemiological studies of HRT use after bladder,
gastric or brain cancer and survival. Although three epi-
demiological studies have investigated HRT use before
lung cancer diagnosis and survival, their results were
conflicting [16–18] and none investigated HRT use after
diagnosis.
The role of oestrogen in cancer is complex, however,
and there is contrasting evidence that oestrogen could
delay cancer progression at several cancer sites. For in-
stance, preclinical studies have shown that oestrogen in-
hibits cell growth and/or induces apoptosis in
oesophageal adenocarcinoma [19] and malignant melan-
oma cell lines [20]. HRT use is associated with a reduced
risk of various cancers including liver [21], non-Hodgkin
lymphoma [22], and colorectal cancer [23]. A number of
studies have investigated hormone replacement therapy
after colorectal cancer [24, 25] and melanoma [26, 27]
but epidemiological evidence at other cancer sites is
sparse. For instance, HRT before diagnosis was associ-
ated with reduced mortality in 234 patients with primary
liver cancer [21], but HRT after diagnosis was not inves-
tigated and in a study of 130 leukaemia patients no ex-
cess recurrences were observed in HRT users [28].
HRT and cardiovascular disease
Studies in the general population have observed that
women taking HRT have increased risks of various car-
diovascular diseases including coronary heart disease
[29], stroke [30] and venous thromboembolism (VTE)
[31], particularly in the first years of use [29]. VTE is of
particular concern as cancer patients are already at in-
creased risk [32] and it is a common cause of death in
cancer patients [33]. Despite this evidence, the risk of
cardiovascular disease, and VTE, in cancer patients using
HRT has not been investigated previously in large epi-
demiological cohorts.
Aims
Our primary aim is to determine the association be-
tween HRT use and the risk of cancer-specific mortality
in women with a range of common cancers. Our sec-
ondary aims are to determine the association between
HRT and risk of all-cause mortality, second cancers, car-
diovascular disease and VTE in women with cancer.
Methods/design
Data sources
The study will utilise the Scottish National Prescribing
Information System (Scotland) [34] and the SAIL data-
bank (Wales) [35]. Data sources were selected because
they have high quality cancer registry data linked to
mortality and prescribing or dispensing data (see Table 1
for details).
Cohorts
Population-based cohorts of newly diagnosed, from 2000
to 2016, incident female cancer patients aged 40 to 79
will be identified within each data source. The eighteen
most common female cancers, excluding breast cancer
(as HRT is generally contraindicated in breast cancer pa-
tients), will be investigated including: lung, colorectal,
cervical, uterine, malignant melanoma, ovarian, non-
Hodgkin’s lymphoma, pancreas, kidney, leukaemia, oral,
bladder, oesophagus, thyroid, multiple myeloma, brain,
gastric and liver. Patients previously diagnosed with
other invasive cancer diagnoses (apart from non-
melanoma skin cancer) will be excluded.
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Exposure
HRT use will be ascertained from electronic general
practitioner (GP) prescribing records (Wales) or dispens-
ing records (Scotland). We will capture both the route of
administration (oral, transdermal, vaginal, injection or
implant) and type of HRT including oestrogen-only
(conjugated equine oestrogen and estradiol) and com-
bined oestrogen with progestogen preparations
(oestrogen with medroxyprogesterone acetate, dydroges-
terone, norethisterone acetate, norgestrel/levonorgestrel,
or drospirenone).
Outcome
The primary outcome will be cancer-specific mortality
(based upon cancer as the underlying cause of death)
from national mortality records (see Table 1). Secondary
outcomes of all-cause mortality (from mortality records),
any second cancer (and by type, from cancer registry re-
cords), and cardiovascular disease (from hospital admis-
sions data or mortality records) including separately
coronary heart disease, stroke, VTE and any cardiovas-
cular disease (based upon coronary heart disease or
stroke), will also be investigated.
Covariates
The following covariates will be identified: age, year, eth-
nicity, stage (from cancer registry records), cancer treat-
ment (including radiotherapy, chemotherapy and
surgery, from cancer registry records), grade (from can-
cer registry records), relevant comorbidities (including
Charlson comorbidity conditions, from hospital admis-
sions in Scotland and GP records and hospital admis-
sions in Wales), medication use (including aspirin,
statins and other medications associated with cancer
survival), hysterectomy/oophorectomy (from hospital ad-
missions in Scotland and hospital admissions and GP re-
cords in Wales), family history of cancer (from GP
records, not available in Scotland), deprivation (based
upon the relevant Index of Multiple Deprivation [34,
35]) and smoking and Body Mass Index (BMI from GP
records, not available in Scotland).
Statistical analysis
Two main analyses will be conducted investigating HRT
use after diagnosis and immediately before diagnosis.
In the analysis of HRT use after diagnosis, patients will
be followed from 6months after cancer diagnosis to
cancer-specific mortality (censored on death from other
causes or end of follow-up). Consequently, patients who
died from any cause in the first 6 months after cancer
diagnosis will be excluded as it seems unlikely that HRT
use after diagnosis could impact upon such deaths (in
sensitivity analyses this duration will be varied, described
later). HRT use will be modelled as a time varying covar-
iate to avoid immortal time bias [36], i.e. patients will be
considered non-users and then users after a lag of 6
months after their first HRT prescription. A lag is rec-
ommended in studies of medication use and cancer sur-
vival [37] as it moves the exposed period forward which
is more likely to reflect when the medication will may
have an impact. A dose-response analysis will be con-
ducted by duration of use based upon daily defined
doses (DDDs) and number of prescriptions. An individ-
ual will be considered a non-user prior to 6 months after
first HRT use, a user of 0 to 1 year of prescriptions from
6months after first prescription to 6 months after their
12th prescription (or 365th DDD) and a greater user
after this time. Time-dependent cox regression models
will be used to calculate hazard ratios (HRs), and 95%
confidence intervals (CIs), for HRT use after cancer
diagnosis adjusting for age, year, ethnicity, stage, cancer
treatment, grade, comorbidities, prior hysterectomy/oo-
phorectomy, medication use (as time-varying covariates)
and deprivation. A two-stage analysis procedure using
random effects models will be conducted to pool results
across cohorts [38]. Separate analyses will be conducted
by type and route of administration of HRT.
In the analysis of HRT before diagnosis, cancer pa-
tients will be followed from diagnosis to cancer-specific
mortality. HRT use will be identified in the 18months
before diagnosis excluding HRT use in the six months
immediately before diagnosis, as depending upon the
cancer drug use can increase in this period due to cancer
symptoms [39]. Cox regression models will be used to
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calculate HRs and 95% CIs for cancer-specific death in
HRT users compared with non-users. Age, year, ethnicity,
comorbidities, prior hysterectomy/oophorectomy and
medication use before diagnosis will be included in these
cox regression models to calculate adjusted HRs and
95%CIs. Stage, grade and cancer treatments will be ex-
cluded from the models investigating HRT before diagno-
sis, as these could lie on the causal pathway. As before
two-stage methods will pool results across cohorts.
A number of additional analyses will be conducted.
First, the main analysis will be repeated additionally
adjusting for characteristics not available in both cohorts
e.g. family history, smoking and BMI (only available in
Welsh data). An analysis will be conducted restricted to
women over age 55 (i.e. post-menopausal women) and
an analysis will be conducted widening the age groups to
include younger women aged 18 to 40 (Scottish data).
An analysis of HRT after diagnosis will be conducted
using a new-user design i.e. restricting analyses to cancer
patients who did not use HRT before diagnosis [40], and
after adjustment for HRT before diagnosis. A separate
analysis will be conducted investigating the timing of
HRT initiation after cancer diagnosis. Analyses of HRT
after diagnosis will be conducted varying the lag from 6
months to 1 and 2 years.
The primary analysis strategy will be repeated for the
secondary outcome of all-cause mortality and second
cancers. A different analysis strategy will be used to in-
vestigate the secondary outcome of cardiovascular dis-
ease and VTE. In these analyses current use of hormone
replacement therapy after cancer diagnosis will be mod-
elled as a time-varying covariate. Patients will become a
current user upon the date of each hormone replace-
ment therapy prescription, and remain a user for the
duration of the prescription, based upon the daily de-
fined dose, plus 30 days to account for any residual ef-
fect. The exposure period from the end of one
prescription plus 30 days to the start of the next will be
allocated to past use. Cox regression models will then be
used to calculate HRs and 95% CI for cardiovascular dis-
ease overall and by type comparing hormone replace-
ment therapy current use and past use to non-users,
adjusting for the confounders mentioned previously.
In general, multiple imputation will be used to impute
missing values particularly for stage, smoking and BMI.
As recommended cancer-specific death status and cu-
mulative hazard will be included in imputation models
[41], along with exposure and confounder variables and
results will be combined using Rubin’s rules. STATA 16
will be used for all analyses.
Sample size calculation
Sample size calculations were conducted based upon the
number of cancer cases in published studies from
Scotland [42, 43], and in Wales based upon published
counts of cases from the Welsh Cancer Intelligence and
Surveillance Unit assuming 90% have GP linked data
(provided by SAIL databank). The number of deaths was
estimated based upon survival at 6 months and 5 years
from English published female survival curves [44]. In
sample size calculations we estimated that 7% of female
cancer patients would use HRT after diagnosis similar to
published reports (e.g. 5% of a Swedish colorectal cancer
cohort used HRT after diagnosis [25], and 9% of a Da-
nish melanoma cohort used HRT after diagnosis [26]).
For instance, we estimate there will be 22,000 colorec-
tal cancer cases diagnosed in Scotland (diagnosed 2009
to 2016) and Wales (diagnosed 2000 to 2016), of whom,
approximately 20% (4400) will die within 6months (and
be removed from analysis of HRT after diagnosis) and a
further 31% (6820) will die within 5 years. Therefore,
based on a cohort of 17,600 colorectal cancer patients
and 6820 cancer-specific deaths, we would have over
80% power to detect, as significant at the 5% level, a HR
for cancer-specific mortality of 1.15 (or 0.85) for HRT
users after diagnosis (i.e. we could detect an increased
risk of cancer-specific mortality in HRT users of 15%)
using Schoenfeld’s method [45]. Similarly, in gastric can-
cer patients, we anticipate 3300 patients and 1181
cancer-specific deaths in the analysis of HRT after diag-
nosis and therefore we would have over 80% power to
detect, as significant at the 5% level, a HR for cancer-
specific mortality of 1.45 for HRT users after diagnosis.
A similar analysis is being conducted in England using
QResearch and we anticipate pooling results across the
three cohorts which will further increase power.
Discussion
These large population cohort studies from Scotland
and Wales will provide real world data on the associ-
ation between HRT use and the risk of cancer-specific
mortality in women with a range of common cancers.
These cohorts will also provide information on the risk
of other potential adverse outcomes of HRT use in can-
cer patients, such as cardiovascular disease, VTE, second
cancers and all-cause mortality. This study will provide
cancer patients and clinicians with evidence on the
safety of HRT in cancer patients, allowing them to make
better informed decisions on whether to use HRT. The
study will also provide important mechanistic insights
into the role of oestrogen in cancer progression.
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